- Details
- Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration (FDA) approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-res...
|
- Details
- The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, the primary author joins Alicia Morgans to provide an update on the PROCEED registry aiming to understand outcomes for Afr...
|
- Details
- In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about systemic treatment sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of their treatment. Biographies: Evan Yu, MD, Medical oncologist, treats pr...
|
- Details
- The ORIOLE Phase 2 Randomized Clinical Trial set out to answer the question, "how effectively does stereotactic ablative radiotherapy prevent progression of disease compared with observation in men with recurrent hormone-sensitive prostate cancer with 1 to 3 metastases?" Dr Tran joins Alicia Morgans and discusses this phase 2 randomized clinical trial of 54 men, where the progression of disease at...
|
- Details
- Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer (mCRPC), that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment h...
|
- Details
- In this discussion on the CARD trial with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from the ASCO GU 2020 presentation: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer from the CARD study. The objective of the QoL analysis was focused on three parti...
|
- Details
- Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer (CRPC). The two review the risks and benefits of either the standard dose of 5mg prednisone BID compared to a lower steroid dose of 5mg daily. Dr. Attard also shares his perspective on using dexamethasone, which has also shown to have an...
|
- Details
- Justin Drake, University of Minnesota, discusses the latest and ongoing research associated with the correlation between RET gene expression and neuroendocrine prostate cancer. The recent data shows enhanced RET gene expression in patients that have this AR negative neuroendocrine positive phenotype. Drake also highlighted his work in the development of noninvasive ways of detecting RET signaling...
|
- Details
- Phuoc Tran, Johns Hopkins University, provides an overview of several ongoing clinical trials for prostate cancer. SALV-ENZA is a Phase II randomized placebo-controlled trial of salvage radiation, which then randomizes to either to placebo or the oral next-generation antiandrogen drug known as enzalutamide. Dr. Tran also reviews the ORIOLE and RAVENS clinical trials which examine metastasis-direct...
|
- Details
- Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...
|
